ABSTRACT Since the outcome of relapsed/refractory aggressive non-Hodgkin’s lymphoma (NHL) is highly variable, a risk-adapted treatment approach was evaluated. After two cycles of DHAP,

patients received high-dose treosulfan/etoposide/carboplatinum (TEC) and autologous stem cell rescue. After TEC, low-risk patients with late relapse (>1 year after first CR who achieved

CR after DHAP received no further treatment. Patients with late relapse who achieved CR or PR only after TEC underwent a second cycle of TEC. High-risk patients with early relapse/refractory

disease received treosulfan/fludarabine followed by allogeneic transplantation. Rituximab was added in patients with B-cell lymphoma (86%). At entry, 36% of all 57 patients had refractory

and 32.6 for those who underwent allogeneic transplantation. International prognostic index (IPI) at study entry was highly discriminative at predicting OS (_P_<0.0001). Risk-adapted,

treosulfan-based therapy with auto- and allo-SCT is feasible. Long-term survival is possible with allogeneic transplantation. Access through your institution Buy or subscribe This is a

preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per

year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated

during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS RITUXIMAB AS

ADJUNCTIVE THERAPY TO BEAM CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA Article 01 February 2022 OXALIPLATIN BEFORE AUTOLOGOUS TRANSPLANTATION IN COMBINATION

WITH HIGH-DOSE CYTARABINE AND RITUXIMAB PROVIDES LONGER DISEASE CONTROL THAN CISPLATIN OR CARBOPLATIN IN PATIENTS WITH MANTLE-CELL LYMPHOMA: RESULTS FROM THE LYMA PROSPECTIVE TRIAL Article

03 March 2021 TREOSULFAN VS BUSULFAN CONDITIONING FOR ALLOGENEIC BMT IN CHILDREN WITH NONMALIGNANT DISEASE: A RANDOMIZED PHASE 2 TRIAL Article Open access 04 November 2023 REFERENCES *

Philip T, Guglielmi C, Hagenbeck A, Somers R, Van der Lelie H, Bron D _et al_. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of

chemotherapy-sensitive non-Hodgkin’s lymphoma. _N Engl J Med_ 1997; 333: 1540–1545. Article  Google Scholar  * Philip T, Armitage O, Spitzer G, Chauvin F, Jagannath S, Cahn JY _et al_. High

dose therapy and autologous bone marrow transplantation in 100 adults with intermediate and high-grade non-Hodgkin’s lymphoma. _N Engl J Med_ 1987; 316: 1493–1498. Article  CAS  Google

Scholar  * Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C _et al_. on behalf of the PARMA cooperative group. Time to relapse has prognostic value in patients with

aggressive lymphoma enrolled in the PARMA trial. _J Clin Oncol_ 1998; 16: 3264–3269. Article  CAS  Google Scholar  * Jones RJ, Ambinder RF, Piantadosi S, Santos GW . Evidence of a

graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. _Blood_ 1991; 77: 649–653. CAS  Google Scholar  * Moreau P, Méchinaud F, Mahé B, Le Tortorec S, Rapp MJ,

Maisonneuve H _et al_. Successful allogeneic bone marrow transplantation for early relapse after autologous bone marrow transplantation in two cases of aggressive high-grade non-Hodgkin’s

lymphoma. _Bone Marrow Transplant_ 1996; 18: 665–667. CAS  PubMed  Google Scholar  * Bernard M, Dauriac C, Drénou B, Leberre C, Branger B, Fauchet R _et al_. Long-term follow-up of

allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin’s lymphoma. _Bone Marrow Transplant_ 1999; 23: 329–333. Article  CAS  Google Scholar  * Dhedin N, Giraudier

S, Gaulard P, Esperou H, Ifrah N, Michallet M _et al_. Allogeneic bone marrow transplantation in aggressive non-Hodgkin’s lymphoma excluding Burkitt and lymphoblastic lymphoma: a series of

73 patients from the SFGM database. _Soiceté Francaise de Greffe de Moelle. Br J Haematol_ 1999; 107: 154–161. Article  CAS  Google Scholar  * Robinson SP, Goldstone AH, Mackinnon S, Carella

A, Russell N, de Elvira CR _et al_. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis

from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. _Blood_ 2002; 100: 4310–4316. Article  CAS  Google Scholar  * Mollee P, Lazarus HM, Lipton J

. Why aren’t we performing more allografts for aggressive non-Hodgkins lymphoma? _Bone Marrow Transplant_ 2003; 31: 953–960. Article  CAS  Google Scholar  * Casper J, Wolff D, Knauf W, Blau

IW, Ruutu T, Volin L _et al_. Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. _J Clin

Oncol_ 2010; 28: 3344–3351. Article  CAS  Google Scholar  * Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F _et al_. Reduced-toxicity conditioning with treosulfan, fludarabin

and ATG as preparative regimen for allogeneic stem cell transplantation in elderly patients with secondary acute myeloid leukemia or myelodysplastic syndrome. _Bone Marrow Transplant_ 2006;

37: 339–344. Article  Google Scholar  * Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM _et al_. Clinical phase I dose escalation and pharmacokinetic study of high-dose

chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. _Clin Cancer Res_ 2000; 6: 4209–4216. CAS  PubMed  Google

Scholar  * Bojko P, Scheulen ME, Hilger R, Oberhoff C, Schindler AE, Seeber S . High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian

cancer. _J Cancer Res Clin Oncol_ 2001; 127: 243–250. Article  CAS  Google Scholar  * Koenigsmann M, Mohren M, Jentsch-Ullrich K, Franke A, Becker E, Heim M _et al_. High-dose treosulfan in

patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. _Bone Marrow Transplant_ 2004; 43: 477–483. Article  Google Scholar  *

Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Tmeny M _et al_. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. _J Clin

Oncol_ 2010; 28: 4184–4190. Article  Google Scholar  * Martin A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM _et al_. R-ESHAP as salvage therapy for patients with relapsed or

refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. _Haematologica_ 2008; 93: 1829–1836. Article  CAS  Google Scholar  *

Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ _et al_. Impact of pretransplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse

large B-cell lymphoma. _Biol Blood Marrow Transplant_ 2009; 15: 1455–1464. Article  CAS  Google Scholar  * Heli U, Eeva J, Anne N, Tapani R, Liisa V . Low incidence and severity of oral

mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine. _Eur J Haematol_ 2012; 88: 87–88. Article  CAS  Google Scholar  * Hensley ML, Hagerty

KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH _et al_. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy

protectants. _J Clin Oncol_ 2009; 27: 127–145. Article  CAS  Google Scholar  * Puig N, de la Rubia J, Remigia MJ, Jarque I, Martin G, Cupelli L _et al_. Morbidity and transplant-related

mortality of CBV and BEAM preparative regiments for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. _Leuk Lymphoma_ 2006; 47: 1488–1494. Article  Google

Scholar  * Jatunen E, Itälä M, Lehtinen T, Kuittinen O, Koivunen E, Leppä S _et al_. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide

survey of 1482 transplanted patients. _Eur J Haematol_ 2006; 76: 25–50. Google Scholar  * Ulrickson M, Aldridge J, Kimt HT, Hochberg EP, Hammermann P, Dube C _et al_. Busulfan and

cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. _Biol Blood Marrow

Transplant_ 2009; 15: 1447–1454. Article  CAS  Google Scholar  * Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M _et al_. Reduced-toxicity conditioning with treosulfan and

fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. _Haematologica_ 2011; 96:

1344–1350. Article  CAS  Google Scholar  * O’Meara A, Halter J, Heim D, Gerull S, Bucher C, Passweg J _et al_. Allogeneic stem cell transplantation for relapsed or refractory lymphoma after

conditioning with BEAM/fludarabine/TBI. _Biol Blood Marrow Transplant_ 2013; 19: 82–86. Article  Google Scholar  * van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP _et

al_. Allogeneic stem cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem cell transplantation: an

analysis of the European Group for Blood and Marrow Transplantation Registry. _J Clin Oncol_ 2011; 29: 1342–1348. Article  Google Scholar  * Thomson KJ, Morris EC, Bloor A, Cook G, Milligan

D, Parker A _et al_. Favorable long term survival after reduced-intensity allogeneic transplantation for multiple-relapsed aggressive non-Hodgkin’s lymphoma. _J Clin Oncol_ 2008; 27:

426–432. Article  Google Scholar  * Bacher U, Klychnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR _et al_. Conditioning regimens for allotransplants for diffuse large B-cell

lymphoma: myeloablative or reduced intensity? _Blood_ 2012; 120: 4256–4262. Article  CAS  Google Scholar  * Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreunschuh M _et al_.

Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. _J Clin Oncol_ 2010; 28: 2373–2380.

Article  CAS  Google Scholar  * Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE _et al_. Molecular subtypes of diffuse B-cell lymphoma arise by distinct genetic pathways. _Proc

Natl Acad Sci USA_ 2008; 105: 13250–13255. Article  Google Scholar  * Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E _et al_. The germinal center / activated B-cell

subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a Bio-CORAL study. _J Clin Oncol_ 2011; 29: 4079–4087. Article

  Google Scholar  * Cuccuini W, Briere J, Mounier N, Voelker HU, Rosenwald A, Sundstrom C _et al_. Myc+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by

BEAM plus autologous stem cell transplantation. _Blood_ 2012; 119: 4619–4624. Article  CAS  Google Scholar  * Perry AM, Cardesa-Salzman TM, Meyer PN, Colomo L, Smith LM, Fu K _et al_. A new

biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. _Blood_ 2012; 120: 2290–2296. Article  CAS  Google Scholar  *

Larouche JF, Berger F, Chassagne-Clément C, Ffrench M, Callet-Bauchu E, Sebban C _et al_. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical

characteristics and outcome. _J Clin Oncol_ 2010; 28: 2094–2100. Article  Google Scholar  * Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE _et al_. Lenalidomid monotherapy in

relapsed or refractory aggressive non-Hodgkin’s lymphoma. _J Clin Oncol_ 2008; 26: 4953–4957. Article  Google Scholar  * Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA

_et al_. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. _Ann Oncol_ 2011; 22: 1622–1627. Article  CAS 

Google Scholar  Download references ACKNOWLEDGEMENTS We thank Professor Dr Astrid Franke, former Director of the Department of Hematology and Oncology, University of Magdeburg, and Professor

Dr Mathias Freund, former Director of the Department of Hematology and Oncology University of Rostock, Germany, for supporting this study. This work was supported (in part) by research

funding by Medac, Gesellschaft für klinische Spezialpräparate mbH, Wedel, Germany; F. Hoffmann-La Roche AG, Grenzach, Germany; and Amgen GmbH, München, Germany (to MK). JC has received

research funding and honoraria from Medac. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Onkologisches Ambulanzzentrum, Hannover, Germany M Koenigsmann * Klinik für Onkologie und Hämatologie

Klinikum, Oldenburg, Germany J Casper & B Metzner * Klinik für Hämatologie und Internistische Onkologie Klinikum, Magdeburg, Germany C Kahl * Medizinische Klinik I, Malteserkrankenhaus

St Franziskus Hospital, Flensburg, Germany N Basara * Abteilung für Hämatologie und Onkologie, Klinik für Innere Medizin II, Universitätsklinik, Jena, Germany H G Sayer * Abteilung für

Hämatologie und Internistische Onkologie, Universitätsklinik, Leipzig, Germany G Behre * Klinik I für Innere Medizin, Universitätsklinik, Köln, Germany S Theurich & D Niederwieser *

Klinik und Poliklinik für Innere Medizin IV, Universitätsklinikum, Halle, Germany M Christopeit * Klinik für Innere Medizin, Johanniter-Krankenhaus, Stendal, Germany M Mohren * Klinik für

Hämatologie und Internistische Onkologie, Universitätsklinikum, Regensburg, Germany A Reichle * Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische

Hochschule, Hannover, Germany A Ganser & M Stadler * Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charité Universitätsmedizin Berlin, Berlin, Germany L Uharek *

Evangelisches Krankenhaus, Hamm, Germany L Balleisen * Wissenschaftlicher Service Pharma GmbH, Langenfeld, Germany A Hinke & R Hinke Authors * M Koenigsmann View author publications You

can also search for this author inPubMed Google Scholar * J Casper View author publications You can also search for this author inPubMed Google Scholar * C Kahl View author publications You

can also search for this author inPubMed Google Scholar * N Basara View author publications You can also search for this author inPubMed Google Scholar * H G Sayer View author publications

You can also search for this author inPubMed Google Scholar * G Behre View author publications You can also search for this author inPubMed Google Scholar * S Theurich View author

publications You can also search for this author inPubMed Google Scholar * M Christopeit View author publications You can also search for this author inPubMed Google Scholar * M Mohren View

author publications You can also search for this author inPubMed Google Scholar * A Reichle View author publications You can also search for this author inPubMed Google Scholar * B Metzner

View author publications You can also search for this author inPubMed Google Scholar * A Ganser View author publications You can also search for this author inPubMed Google Scholar * M

Stadler View author publications You can also search for this author inPubMed Google Scholar * L Uharek View author publications You can also search for this author inPubMed Google Scholar *

L Balleisen View author publications You can also search for this author inPubMed Google Scholar * A Hinke View author publications You can also search for this author inPubMed Google

Scholar * R Hinke View author publications You can also search for this author inPubMed Google Scholar * D Niederwieser View author publications You can also search for this author inPubMed 

Google Scholar CORRESPONDING AUTHOR Correspondence to M Koenigsmann. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no conflict of interest. ADDITIONAL INFORMATION Supplementary

Information accompanies this paper on Bone Marrow Transplantation website SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION (DOC 119 KB) RIGHTS AND PERMISSIONS Reprints and permissions

ABOUT THIS ARTICLE CITE THIS ARTICLE Koenigsmann, M., Casper, J., Kahl, C. _et al._ Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a

prospective phase-II trial. _Bone Marrow Transplant_ 49, 410–415 (2014). https://doi.org/10.1038/bmt.2013.199 Download citation * Received: 22 June 2013 * Revised: 16 October 2013 *

Accepted: 25 October 2013 * Published: 23 December 2013 * Issue Date: March 2014 * DOI: https://doi.org/10.1038/bmt.2013.199 SHARE THIS ARTICLE Anyone you share the following link with will

be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt

content-sharing initiative KEYWORDS * relapsed non-Hogkin’s lymphoma * treosulfan * autologous transplantation * allogeneic transplantation * risk-adapted therapy